Test Id : AHPRU
Antihypertension Panel, Random, Urine
Useful For
Suggests clinical disorders or settings where the test may be helpful
Aid in the management of hypertension, especially treatment resistant hypertension
Monitoring compliance in individuals prescribed antihypertensive drug therapy
As a screen for to detect nonprescribed use of common diuretics
Method Name
A short description of the method used to perform the test
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.
Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test
Aliases
Lists additional common names for a test, as an aid in searching
Apparent treatment resistant hypertension
Norvasc
Amvaz
Istin
Tenormin
Senormin
Tenoblock
Bumex
Burinex
Coreg
Carvil
Eucardic
Hygroton
Thalitone
Chlorthalid
Catapres
Kapvay
Duraclon
Cardura
Cardular
Lasix
Froop
Frumil
Apresoline
Hydral
Apressin
HCTZ
Microzide
Esidrix
Trandate
Normodyne
Labetex
Prinivil
Zestril
Acerbon
Cozaar
Hyzaar
Losatec
Lopressor
Toprol-XL
Betaloc
Aldactone
Spiractin
Spirohexal
Hytrin
Zayasel
Terapress
Demadex
Torasemide
Torem
Specimen Type
Describes the specimen type validated for testing
Urine
Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Container/Tube: Plastic, 5-mL tube
Specimen Volume: 4 mL
Collection Instructions:
1. Collect a random urine specimen.
2. No preservative
Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the testing laboratory. The minimum volume is sufficient for one attempt at testing.
1 mL
Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected
Gross hemolysis | Reject |
Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Urine | Refrigerated (preferred) | 14 days | |
Ambient | 7 days | ||
Frozen | 14 days |
Useful For
Suggests clinical disorders or settings where the test may be helpful
Aid in the management of hypertension, especially treatment resistant hypertension
Monitoring compliance in individuals prescribed antihypertensive drug therapy
As a screen for to detect nonprescribed use of common diuretics
Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Adherence to antihypertensive medication dose and frequency is important for adequate hypertension control. Not taking medications as prescribed is a common and underappreciated cause of resistant hypertension. It can be challenging to suspect and discern medication nonadherence from history alone. This urine assay includes drug targets that are commonly prescribed for hypertension and allows for an objective assessment of whether a patient has taken a prescribed medication in the previous twenty-four hours. If not, a healthcare professional can explore the reason for noncompliance with the patient in a targeted fashion. If there are issues with patient tolerance of a given medication not previously appreciated, alternative regimens can be considered. This targeted information can also help avoid over prescription of additional medications and related complications.
This test can also be used as a screen to detect nonprescribed use of common diuretics.
Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
Not detected: These drugs should not be present in untreated individuals.
Cutoff concentrations:
Amlodipine: 400 ng/mL
Atenolol: 800 ng/mL
Bumetanide: 40 ng/mL
Carvedilol: 40 ng/mL
Chlorthalidone: 4 ng/mL
Clonidine: 40 ng/mL
Furosemide: 4 ng/mL
Hydralazine: 400 ng/mL
Hydrochlorothiazide: 10 ng/mL
Labetalol: 40 ng/mL
Lisinopril: 1000 ng/mL
Losartan: 4 ng/mL
Metoprolol: 40 ng/mL
7-alpha-Thiomethylspironolactone: 10 ng/mL
Terazosin: 4 ng/mL
Torsemide: 40 ng/mL
Interpretation
Provides information to assist in interpretation of the test results
Antihypertensive medications are reported as either detected or not detected, specific concentrations are not quantified.
This test measures urine concentrations of 7 alpha-thiomethylspironolactone, a major active metabolite of spironolactone. Detection of this metabolite indicates recent intake of spironolactone and can be used to assess patient compliance with spironolactone therapy.
Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
Results should be interpreted in context with the patient’s prescribed medications.
Clinical Reference
Recommendations for in-depth reading of a clinical nature
1. Gupta P, Patel P, Strauch B, et al. Biochemical screening for nonadherence is associated with blood pressure reduction and improvement in adherence. Hypertension. 2017;70(5):1042-1048. doi:10.1161/Hypertensionaha
2. Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31(4):766-774. doi:10.1097/HJH.0b013e32835e2286
3. Tomaszewski M, White C, Patel P, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart. 2014;100(11):855-861. doi:10.1136/heartjnl-2013-305063
4. Peeters LEJ, Kappers MHW, Boersma E, et al. The effect of combining therapeutic drug monitoring of antihypertensive drugs with personalised feedback on adherence and resistant hypertension: the (RHYME-RCT) trial protocol of a multi-centre randomised controlled trial. BMC Cardiovasc Disord. 2023;23(1):87. doi:10.1186/s12872-023-03114-0
Method Description
Describes how the test is performed and provides a method-specific reference
Antihypertensives are separated and quantified in urine by liquid chromatography tandem mass spectrometry.(Unpublished Mayo method)
PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information
Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.
Friday
Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.
Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Performing Laboratory Location
Indicates the location of the laboratory that performs the test
Fees :
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact Customer Service.
Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.
CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
CPT codes are provided by the performing laboratory.
CPT codes are provided by the performing laboratory.
80377
G0481 (if appropriate)
LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
AHPRU | Antihypertension Panel, Random, U | 107229-7 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
621682 | Amlodipine, Random, U | 107228-9 |
621683 | Atenolol, Random, U | 3360-5 |
621684 | Bumetanide, Random, U | 3409-0 |
621685 | Carvedilol, Random, U | 107227-1 |
621686 | Chlorthalidone, Random, U | 3478-5 |
621687 | Clonidine, Random, U | 52960-2 |
621689 | Furosemide, Random, U | 3660-8 |
621690 | Hydralazine, Random, U | 16983-9 |
621691 | Hydrochlorothiazide, Random, U | 3676-4 |
621692 | Labetalol, Random, U | 3705-1 |
621693 | Lisinopril, Random, U | 107225-5 |
621694 | Losartan, Random, U | 107224-8 |
621695 | Metoprolol, Random, U | 3816-6 |
621696 | 7a-Thiomethylspironolactone, R, U | 12318-2 |
621697 | Terazosin, Random, U | 107223-0 |
621698 | Torsemide, Random, U | 107222-2 |
621688 | Interpretation, Random, U | 59462-2 |
Test Setup Resources
Setup Files
Test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.
Sample Reports
Normal and Abnormal sample reports are provided as references for report appearance.
SI Sample Reports
International System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.
Test Update Resources
Change Type | Effective Date |
---|---|
New Test | 2025-06-24 |